Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA known ✓ | P42336 | 1/20 | 0.50 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.38 |
| ▸ | CD44 | P16070 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | CASP1 | P29466 | 2/20 | 0.53 |
| ▸ | CASP7 | P55210 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17110965 | 1.00 | CD44 (0.58) | CD44CYP3A4ALOX15CASP1CASP7 | |
| Hydrochloric Acid SCHEMBL7784412 | 1.00 | CD44 (0.58) | CD44CYP3A4ALOX15CASP1CASP7 | |
| SCHEMBL94635 | 0.96 | — | — | |
| Ammonia Solution, Strong SCHEMBL28226111 | 0.92 | CD44 (0.58) | CD44CYP3A4ALOX15CASP1CASP7 | |
| SCHEMBL28448539 | 0.92 | CD44 (0.58) | CD44CYP3A4ALOX15CASP1CASP7 | |
| Methane SCHEMBL28191162 | 0.92 | CD44 (0.58) | CD44CYP3A4ALOX15CASP1CASP7 | |
| SCHEMBL30335755 | 0.92 | CD44 (0.58) | CD44CYP3A4ALOX15CASP1CASP7 | |
| SCHEMBL28450972 | 0.92 | CD44 (0.58) | CD44CYP3A4ALOX15CASP1CASP7 | |
| Charcoal, Activated SCHEMBL29548810 | 0.92 | CD44 (0.58) | CD44CYP3A4ALOX15CASP1CASP7 | |
| SCHEMBL28288730 | 0.92 | CD44 (0.58) | CD44CYP3A4ALOX15CASP1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109097032-A | The preparation method of carbon quantum dot fluorescent material and its application in copper ion detection | 上海大学 | 2018-12-28 | — | — | CN | claimed |
| CN-109054292-A | A kind of preparation method of thermally conductive porous graphene-epoxy resin composite material | 安徽赤诚塑胶科技有限公司 | 2018-12-21 | — | — | CN | claimed |
| CN-108641301-A | A kind of preparation method of heat conduction porous graphene-epoxy resin composite material | 芜湖市艾德森自动化设备有限公司 | 2018-10-12 | — | — | CN | claimed |
| CN-108328607-A | Nitrogen, the chlorine of a kind of double transmittings of super-small blue green light are co-doped with graphene quantum dot and preparation method thereof | 吉林师范大学 | 2018-07-27 | — | — | CN | claimed |
| CN-116479366-B | Chemical activation of self-passivating metals | 斯瓦戈洛克公司 | 2025-05-23 | — | — | CN | disclosed |
| US-12071404-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | UCB PHARMA GMBH (DE) | 2024-08-27 | — | — | US | disclosed |
| US-11820746-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | UCB PHARMA GMBH (DE) | 2023-11-21 | — | — | US | disclosed |
| US-20230348384-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | UCB PHARMA GMBH (DE) | 2023-11-02 | — | — | US | disclosed |
| CN-116479366-A | Chemical activation of self-passivating metals | 斯瓦戈洛克公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-116283712-A | (aza) indole-, benzothiophene-and benzofuran-3-sulfonamides | 优时比制药有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-11649538-B2 | Chemical activation of self-passivating metals | SWAGELOK COMPANY (US) | 2023-05-16 | — | — | US | disclosed |
| CN-112236540-B | Chemical activation of self-passivating metals | 斯瓦戈洛克公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-108219453-A | Preparation method of three-dimensional porous graphene/polyaniline composite material | 沈阳大学 | 2018-06-29 | — | — | CN | disclosed |
| CN-108219453-A | Preparation method of three-dimensional porous graphene/polyaniline composite material | 沈阳大学 | 2018-06-29 | — | — | CN | disclosed |
| CN-102041576-B | Polyimide fiber and preparation method thereof | CHANGCHUN APPLIED CHEMISTRY | 2012-04-18 | — | — | CN | disclosed |
| CN-102041576-A | Polyimide fibers and preparation method thereof | CHANGCHUN APPLIED CHEMISTRY | 2011-05-04 | — | — | CN | disclosed |
| CN-1466572-A | Pyrrole derivatives | ס����ҩ��ʽ���� | 2004-01-07 | — | — | CN | disclosed |
| WO-1992013855-A1 | (2-IMIDAZOLIN-2-YLAMINO) TETRAHYDROQUINOLAXINES AND METHODS FOR USING SAME | ALLERGAN, INC. (US) | 1992-08-20 | — | — | WO | disclosed |
| EP-0426390-A2 | Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure | ALLERGAN, INC. (US) | 1991-05-08 | — | — | EP | disclosed |
| EP-0422878-A1 | (2-Imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same | ALLERGAN, INC. (US) | 1991-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820746-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | GPR17, GPR18, GPR27 | PIK3CA 4636/4885GAA 2280/4885CD44 3266/4885 |
| US-20230348384-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | GPR17, GPR18, GPR27 | PIK3CA 4636/4885GAA 2280/4885CD44 3266/4885 |
| US-12071404-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | GPR17, GPR18, GPR27 | PIK3CA 4636/4885GAA 2280/4885CD44 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.